Best Peptide Protocols
    GuideFeb 20, 202610 min

    Peptide Cycling: On/Off Protocols for the Most Common Research Stacks

    Should you cycle peptides? Which ones require breaks and which can be used continuously? A research-based guide to on/off protocols across every major peptide category.

    Why Cycling Matters — And When It Doesn't

    The concept of "cycling" in peptide research refers to alternating periods of administration ("on") with periods of abstention ("off"). The rationale depends on the peptide and its mechanism — and the answer is different for nearly every compound on this site.

    There are three reasons a peptide protocol might include an off cycle:

  1. Receptor desensitization: Some peptides, when administered continuously, cause their target receptors to downregulate — reducing sensitivity and requiring higher doses for the same effect over time. An off cycle allows receptor density to recover.
  2. Feedback suppression: Some hormonal peptides, if used continuously, suppress the natural production of the hormones they're meant to enhance. Cycling prevents chronic suppression.
  3. Tolerance and tachyphylaxis: Rapid reduction in effect after initial doses, distinct from receptor downregulation — more about signal adaptation than receptor density changes.

    4. The fourth possibility — no cycling needed — applies to many compounds where receptor downregulation is not a feature and no feedback suppression occurs.

    Category-by-Category Cycling Guide

    Growth Hormone Secretagogues: Cycling Required

    This is the category where cycling matters most clearly.

    Ipamorelin, GHRP-6, GHRP-2, Hexarelin All GH-releasing peptides (GHRPs) work through the ghrelin receptor (GHS-R1a). Chronic continuous activation of this receptor causes well-documented desensitization — progressively reducing the GH pulse magnitude over weeks of uninterrupted use.

  4. Standard protocol: 8–12 weeks on, 4–6 weeks off
  5. Why: GHS-R1a receptor desensitization; GH pituitary blunting
  6. Hexarelin note: Particularly prone to rapid desensitization — some research protocols use 4–6 weeks on maximum before a mandatory break

    7. CJC-1295 No DAC, Sermorelin (GHRH analogs) GHRH receptor analogs work differently — they stimulate through the GHRH receptor, which is less prone to the acute desensitization seen with GHS-R agonists. However, long-term continuous use can suppress endogenous GHRH production.

  7. Standard protocol: 12–16 weeks on, 4–8 weeks off
  8. Why: Preserves endogenous GHRH rhythm; maintains receptor sensitivity
  9. Sermorelin: Designed to mimic natural pulsatile patterns; some research continues for longer periods without off cycles

    10. CJC-1295 DAC The long-acting DAC version maintains persistent GHRH receptor stimulation rather than pulsatile. This continuous stimulation requires longer off cycles.

  10. Standard protocol: 8–10 weeks on, 4–6 weeks off
  11. Why: DAC's persistent action provides more constant receptor stimulation; off cycles more important than with no-DAC

    12. Ipamorelin + CJC-1295 (the common stack) When these two are combined, the amplified GH pulse means more robust receptor response — but also potentially faster desensitization of the ghrelin receptor.

  12. Standard protocol: 8–12 weeks on, 4 weeks off minimum

    13. GLP-1/2/3 Peptides: No Cycling Required

    Semaglutide, tirzepatide, and retatrutide are studied as continuous weekly therapies in clinical trials — 72–80 weeks without cycling is standard in TRIUMPH and SURMOUNT programs. The GLP-1 receptor does not appear to desensitize meaningfully in clinical use; in fact, clinical trial data consistently shows maintained or improving weight loss over time without tolerance developing.

  13. Cycling: Not required for metabolic endpoints
  14. Protocol: Continuous weekly dosing; dose escalation over weeks 1–8, then maintenance
  15. Off period: Only for clinical reasons (e.g., surgical procedures, pregnancy)

    16. BPC-157: Cycling Recommended

    BPC-157's primary mechanisms (VEGFR2 upregulation, eNOS coupling) appear tissue-repair focused. In animal research, continuous BPC-157 administration does not show pronounced receptor desensitization in the way GHRPs do. However, research protocols typically cycle because:

  16. Tissue repair timelines are finite — once a specific injury has healed, ongoing administration has diminishing rationale
  17. Long-term continuous use at high doses has not been studied in humans
  18. Gastrointestinal biological activity may change with chronic administration
  19. Standard protocol: 4–8 weeks on, 2–4 weeks off
  20. Alternative: Some researchers use BPC-157 in acute "loading" protocols specifically around injury or post-surgery windows

    21. TB-500: Similar to BPC-157

  21. Standard protocol: 4–8 weeks on (loading phase), followed by maintenance dosing or off cycle
  22. Loading: 2–5 mg per week for 4–6 weeks
  23. Maintenance: 2–5 mg bi-weekly or monthly if continuing

    24. NAD+: Continuous Use Supported

    NAD+ is a coenzyme, not a hormone or receptor agonist. There is no receptor to desensitize and no natural production to suppress. Human studies have used continuous daily or weekly administration for months without tapering protocols.

  24. Cycling: Not required
  25. Protocol: Daily or several times weekly; ongoing continuous use is the research norm

    26. GHK-Cu: Continuous Use Supported

    GHK-Cu's gene regulatory mechanism operates through epigenetic changes rather than receptor activation. No desensitization pattern has been established. Cosmetic research typically uses continuous topical application.

  26. Cycling: Not required
  27. Protocol: Daily subcutaneous administration or continuous topical application; no established off-cycle need

    28. Epithalon: Short Cycle Protocols

    Epithalon (Epitalon) was studied in Khavinson's longevity research using discrete course-based protocols — not continuous administration. The original research used 10-day courses once or twice per year, reflecting its intended use as a bioregulatory intervention rather than a daily supplement.

  28. Standard protocol: 10 mg/day for 10 days (one course), 1–2× per year
  29. Why: Telomerase activation may persist beyond the dosing period; discrete courses match the bioregulator research model

    30. MOTS-c: Cycle-Based Research

    Animal research examining MOTS-c's metabolic effects typically uses discrete injection periods (daily for 3–4 weeks) followed by observation periods rather than continuous administration.

  30. Standard protocol: Daily injection for 3–4 weeks; 2–4 week observation/off period
  31. Why: Metabolic improvements may persist beyond active dosing; receptor sensitivity preservation

    32. Semax and Selank: Short Cycles

    Both Russian cognitive peptides are studied in discrete courses in their home clinical context — not as indefinitely continuous compounds.

  32. Standard protocol: 2–4 weeks on, 2–4 weeks off
  33. Why: BDNF upregulation effects may persist after dosing ends; cyclical use maintains responsiveness
  34. Selank: Sometimes shorter cycles (2 weeks on, 1–2 weeks off) due to mild profile

    35. SS-31: Cycle-Based

    SS-31 (Elamipretide) research in mitochondrial disease contexts has used discrete treatment periods rather than continuous administration.

  35. Standard protocol: 4 weeks on, 2–4 weeks off
  36. Why: Cardiolipin stabilization effects may persist post-dose; mitochondrial membrane dynamics benefit from rest periods

    37. Quick Reference: Cycling Summary

    Peptide CategoryCyclingTypical Protocol
    GHRPs (Ipamorelin, GHRP-6)Required8–12 wks on / 4–6 wks off
    GHRH analogs (CJC, Sermorelin)Recommended12–16 wks on / 4–8 wks off
    GLP-1/2/3 (Semaglutide etc.)Not requiredContinuous weekly dosing
    BPC-157Recommended4–8 wks on / 2–4 wks off
    TB-500Recommended4–8 wks loading, then maintenance
    NAD+Not requiredContinuous
    GHK-CuNot requiredContinuous
    EpithalonShort courses10 days, 1–2× per year
    MOTS-cRecommended3–4 wks on / 2–4 wks off
    Semax / SelankRecommended2–4 wks on / 2–4 wks off
    SS-31Recommended4 wks on / 2–4 wks off

    Stacking and Combined Cycling

    When multiple peptides are stacked, cycling schedules compound. Practical approaches:

    Simultaneous cycling: All compounds in the stack follow the same on/off schedule. Simple and clean, but means full breaks from all benefits simultaneously.

    Staggered cycling: Compounds rotate — while GHRPs are in their off phase, BPC-157 continues, or vice versa. More complex to manage but maintains some benefit during all periods.

    Category-based scheduling: GH secretagogues cycle on their own schedule; metabolic peptides (GLP-1) continue; longevity compounds (NAD+, GHK-Cu) continue indefinitely. This is the most common practical approach.

    Important Note

    This article is for educational and research reference purposes only. Cycling recommendations are based on the available research literature and mechanistic reasoning. Individual responses may vary significantly, and no cycling protocol should be interpreted as medical advice.